Washington, DC, USA , 14 November 2026
CureGene Pharmaceutical has presented two new preclinical research studies of CG-0416, its investigational oral, liver-targeted thyroid hormone receptor beta (THR-β) agonist, at Obesity Week 2026 in Washington, DC, highlighting its potential role in obesity management, combination therapy and long-term weight maintenance. The research was presented as Poster-208 on 14 November 2026 and focused on two major challenges associated with current obesity treatments: achieving greater weight reduction while potentially lowering the dose of glucagon-like peptide-1 (GLP-1) receptor agonists, and maintaining weight loss after discontinuation of GLP-1-based treatment. Both studies evaluated CG-0416 using diet-induced obese (DIO) mouse models. According to the company, the findings demonstrated improved weight reduction when CG-0416 was combined with a reduced-dose GLP-1 receptor agonist and slower weight regain when CG-0416 treatment continued after GLP-1 therapy was discontinued. The findings highlight an emerging pharmaceutical research approach focused not only on reducing body weight but also on supporting sustainable metabolic health.
CG-0416 Combination Therapy Demonstrates Greater Weight Reduction
The first preclinical study investigated whether combining CG-0416 with a reduced dose of a GLP-1 receptor agonist could produce greater weight reduction than treatment with a full dose of the GLP-1 receptor agonist alone. CG-0416 is an oral, liver-targeted hydrolysis prodrug designed to activate thyroid hormone receptor beta (THR-β), a receptor involved in regulating liver metabolism and lipid processing. Unlike GLP-1 receptor agonists, which primarily influence appetite regulation and glucose metabolism through incretin pathways, CG-0416 is designed to act in the liver by promoting fat breakdown and increasing thermogenesis. In the combination study, the researchers reported a 35.2% reduction in body weight in the group receiving CG-0416 alongside a reduced-dose GLP-1 receptor agonist, compared with a 7.6% reduction in the group receiving the full-dose GLP-1 receptor agonist alone. This represented approximately 3.6 times greater weight reduction in the experimental mouse model. The company also reported that food intake did not increase with the combination treatment, suggesting that the observed weight reduction was not simply associated with reduced food consumption. These findings indicate potential complementary mechanisms between the two drug classes and support further investigation of combination-based obesity treatments. However, the results remain preclinical and require confirmation through human clinical trials.
CG-0416 Shows Potential to Reduce Weight Regain After GLP-1 Discontinuation
The second study examined whether CG-0416 could help maintain weight reduction after stopping GLP-1 receptor agonist treatment. Weight regain following discontinuation of obesity medication remains an important challenge in long-term obesity management, creating a need for treatment strategies that support sustained metabolic benefits. In this study, diet-induced obese mice initially received a combination of CG-0416 and a GLP-1 receptor agonist. Researchers subsequently discontinued the GLP-1 treatment while continuing CG-0416 as a standalone therapy. According to CureGene, animals receiving continued CG-0416 treatment experienced approximately 38% less weight regain compared with the control group. The study also reported improved body composition measurements, including approximately 10% better lean-mass preservation and 12.1% lower fat mass compared with the control group. These observations suggest that CG-0416 may have potential as a sequential maintenance treatment following GLP-1 therapy. The research is particularly relevant to pharmaceutical development because maintaining weight reduction and preserving lean tissue are important considerations when evaluating long-term obesity treatments. Nevertheless, these findings were obtained in animal models and should not be interpreted as demonstrated clinical benefits in humans.
CureGene Advances CG-0416 Towards Clinical Development
The two presentations form part of CureGene’s broader pharmaceutical development programme for CG-0416, which was developed using the company’s proprietary A-ProX prodrug platform. The technology is designed to improve drug delivery to targeted organs by using enzymatic hydrolysis to release the active compound in the intended tissue. For CG-0416, the approach aims to achieve higher drug activity in the liver while limiting systemic exposure and potential off-target effects. Beyond weight management, the company is also investigating its potential effects on liver fat, lipid profiles and glucose tolerance. Importantly, CG-0416 has already advanced beyond preclinical research into early-stage human evaluation. CureGene reported that Phase I clinical trials are underway in Australia, while a separate Phase I study in China is planned. These clinical studies will be important for evaluating the investigational drug’s safety, tolerability, pharmacokinetics and pharmacodynamic properties in humans. The company presented the latest preclinical findings at Obesity Week 2026, an international scientific meeting organised by The Obesity Society, which brings together researchers, clinicians and pharmaceutical industry professionals to discuss developments in obesity prevention, treatment and metabolic research.
The presentation of these two studies marks another development in innovative obesity drug research and metabolic disease treatment. By exploring combination therapy, weight maintenance and liver-targeted drug delivery, CureGene aims to address important limitations in existing obesity treatment approaches. While the reported animal-study results are promising, further clinical investigation will be necessary to establish the safety, effectiveness and long-term benefits of CG-0416 in humans.
Source: CureGene press release



